#151431

Anti-CD21 [BU32]

Cat. #151431

Anti-CD21 [BU32]

Cat. #: 151431

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Complement component (3d/Epstein Barr virus) receptor 2 (CR2, CD21)

Class: Monoclonal

Application: WB ; FACS ; IHC ; IF

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Birmingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD21 [BU32]
  • Alternate name: Complement Component 3d Receptor 2; Epstein-Barr Virus Receptor 2; Complement C3d Receptor; EBV Receptor; C3DR; CD21 Antigen; CVID7; SLEB9; CD21; Cr2; CR
  • Research fields: Cell signaling and signal transduction;Immunology
  • Clone: BU32
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Purpose: Marker
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: WB ; FACS ; IHC ; IF
  • Description: CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and ...
  • Immunogen: Myeloma cell line Rob
  • Isotype: IgG1
  • Myeloma used: NS0

Target Details

  • Target: Complement component (3d/Epstein Barr virus) receptor 2 (CR2, CD21)
  • Tissue cell line specificity: Mouse
  • Target background: CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and ...

Applications

  • Application: WB ; FACS ; IHC ; IF

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Knapp, W. et al. eds. 1989. Leucocyte Typing IV Oxford University Press. ISBN-13: 978-0192618672
  • Leucocyte Typing III 1987. ISBN-13: 978-0192615527
  • Leucocyte Typing V 1995. ISBN-13: 978-0192623768
  • Leucocyte Typing VI 1998. Garland Publishing NY. ISBN-13: 978-0815327455
  • Ling, NR., Brown, B., Immunobiology (1992) 185(2-4) pp403-14
  • Jackson et al. 2020. BMC Genet. 21(1):101. PMID: 32907542.
  • Herishanu et al. 2013. J Immunol. 190(2):784-93. PMID: 23241880.
  • Masilamani et al. 2004. Rheu...